1-20 of 116
Sort by
News

CAR-T Produces Good Long-Term Outcomes in R/R CLL, Analysis Finds

Thomas R. Collins
Published: 2024
Abstract
January 2025
View News titled, CAR-T Produces Good Long-Term Outcomes in R/R CLL, Analysis Finds
News

Bispecific Antibody Elicits High Responses Among Patients With Heavily Pretreated CLL

Anna Azvolinsky, PhD
Published: 2024
Abstract
January 2025
View News titled, Bispecific Antibody Elicits High Responses Among Patients With Heavily Pretreated CLL
News

MRD-Guided Therapy Improves Quality of Life for Patients With CLL

Anna Azvolinsky, PhD
Published: 2024
Abstract
January 2025
View News titled, MRD-Guided Therapy Improves Quality of Life for Patients With CLL
News

Pirtobrutinib Combinations Effective in Small Study

Thomas R. Collins
Published: 2024
Abstract
December Supplement 2024
View News titled, Pirtobrutinib Combinations Effective in Small Study
News

Analysis Finds CLL-IPI Performs Poorly When Predicting Survival for Patients Treated With Targeted Therapies

Lara C. Pullen, PhD
Published: 2024
Abstract
December Supplement 2024
View News titled, Analysis Finds CLL-IPI Performs Poorly When Predicting Survival for Patients Treated With Targeted Therapies
News

CAR-T Therapy Effective for Richter Transformation

Lara C. Pullen, PhD
Published: 2024
Abstract
December Supplement 2024
View News titled, CAR-T Therapy Effective for Richter Transformation
News

Venetoclax Plus Obinutuzumab a Viable Option for Newly Diagnosed CLL

Anna Azvolinsky, PhD
Published: 2024
Abstract
December Supplement 2024
View News titled, Venetoclax Plus Obinutuzumab a Viable Option for Newly Diagnosed CLL
News

MRD Helpful in Predicting Progression-Free Survival in CLL

Thomas R. Collins
Published: 2024
Abstract
December Supplement 2024
View News titled, MRD Helpful in Predicting Progression-Free Survival in CLL
News

Long-Lasting, Deep Remissions Seen in R/R CLL with Triple Combination Therapy

Anna Azvolinsky, PhD
Published: 2024
Abstract
December Supplement 2024
View News titled, Long-Lasting, Deep Remissions Seen in R/R CLL with Triple Combination Therapy
News

CLL Precursor Condition Linked with Melanoma Risk

Leah Lawrence
Published: 2024
Abstract
Mid-November 2024
View News titled, CLL Precursor Condition Linked with Melanoma Risk
News

Forging a New Standard of Care for Hairy Cell Leukemia

Anna Azvolinsky, PhD
Published: 2024
Abstract
October 2024
View News titled, Forging a New Standard of Care for Hairy Cell Leukemia
News

Fixed-Duration Regimen Safe, Effective for CLL

Lara C. Pullen, PhD
Published: 2024
Abstract
October 2024
View News titled, Fixed-Duration Regimen Safe, Effective for CLL
News

Phase II CAPTIVATE Study: The 5.5-Year Update

Lara C. Pullen, PhD
Published: 2024
Abstract
Mid-July 2024
View News titled, Phase II CAPTIVATE Study: The 5.5-Year Update
News

Fewer Patients With CLL/SLL Switch From Zanubrutinib to Another BTKi

Ruth Jessen Hickman, MD
Published: 2024
Abstract
Mid-July 2024
View News titled, Fewer Patients With CLL/SLL Switch From Zanubrutinib to Another BTKi
News

Asciminib More Effective, Safer Than Frontline Tyrosine Kinase Inhibitors for CML

Katie Robinson
Published: 2024
Abstract
Mid-July 2024
View News titled, Asciminib More Effective, Safer Than Frontline Tyrosine Kinase Inhibitors for CML
News

AI Electrocardiography Predicts Atrial Fibrillation Risk in Patients with CLL

Lara C. Pullen, PhD
Published: 2024
Abstract
July 2024
View News titled, AI Electrocardiography Predicts Atrial Fibrillation Risk in Patients with CLL
News

KIR3DL1-HLA-Bw Status in CML Is Associated With Achievement of Treatment-Free Remission

Lara C. Pullen, PhD
Published: 2024
Abstract
May 2024
View News titled, KIR3DL1-HLA-Bw Status in CML Is Associated With Achievement of Treatment-Free Remission
News

In the Long Run, Ibrutinib Brings Disease Control, but Cardiac Risks, in Older Patients with Untreated CLL

Thomas R. Collins
Published: 2024
Abstract
March 2024
View News titled, In the Long Run, Ibrutinib Brings Disease Control, but Cardiac Risks, in Older Patients with Untreated CLL
News

Researchers Identify Possible New Targets in CLL Subtypes

Thomas R. Collins
Published: 2023
Abstract
January Supplement 2024
View News titled, Researchers Identify Possible New Targets in CLL Subtypes
News

Flow Cytometry Identified as Less Expensive Method to Learn IGHV Status in CLL

Thomas R. Collins
Published: 2023
Abstract
January Supplement 2024
View News titled, Flow Cytometry Identified as Less Expensive Method to Learn IGHV Status in CLL